These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 29687050

  • 1. Correlation of apparent diffusion coefficient ratio on 3.0 T MRI with prostate cancer Gleason score.
    Jyoti R, Jain TP, Haxhimolla H, Liddell H, Barrett SE.
    Eur J Radiol Open; 2018; 5():58-63. PubMed ID: 29687050
    [Abstract] [Full Text] [Related]

  • 2. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L.
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [Abstract] [Full Text] [Related]

  • 3. Apparent Diffusion Coefficient (ADC) Ratio Versus Conventional ADC for Detecting Clinically Significant Prostate Cancer With 3-T MRI.
    Bajgiran AM, Mirak SA, Sung K, Sisk AE, Reiter RE, Raman SS.
    AJR Am J Roentgenol; 2019 Sep; 213(3):W134-W142. PubMed ID: 31216201
    [Abstract] [Full Text] [Related]

  • 4. Diffusion-weighted imaging of the prostate: should we use quantitative metrics to better characterize focal lesions originating in the peripheral zone?
    Pierre T, Cornud F, Colléter L, Beuvon F, Foissac F, Delongchamps NB, Legmann P.
    Eur Radiol; 2018 May; 28(5):2236-2245. PubMed ID: 29168004
    [Abstract] [Full Text] [Related]

  • 5. Apparent diffusion coefficient ratio correlates significantly with prostate cancer gleason score at final pathology.
    Boesen L, Chabanova E, Løgager V, Balslev I, Thomsen HS.
    J Magn Reson Imaging; 2015 Aug; 42(2):446-53. PubMed ID: 25408104
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of single-scanner single-protocol quantitative ADC measurements to ADC ratios to detect clinically significant prostate cancer.
    Wang X, Hielscher T, Radtke JP, Görtz M, Schütz V, Kuder TA, Gnirs R, Schwab C, Stenzinger A, Hohenfellner M, Schlemmer HP, Bonekamp D.
    Eur J Radiol; 2021 Mar; 136():109538. PubMed ID: 33482592
    [Abstract] [Full Text] [Related]

  • 14. The Utility of Diffusion-Weighted Imaging and Perfusion Magnetic Resonance Imaging Parameters for Detecting Clinically Significant Prostate Cancer.
    Cindil E, Oner Y, Sendur HN, Ozdemir H, Gazel E, Tunc L, Cerit MN.
    Can Assoc Radiol J; 2019 Nov; 70(4):441-451. PubMed ID: 31561925
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Analysis of Diffusion-weighted MR Images Based on a Gamma Distribution Model to Differentiate Prostate Cancers with Different Gleason Score.
    Tomita H, Soga S, Suyama Y, Ito K, Asano T, Shinmoto H.
    Magn Reson Med Sci; 2020 Feb 10; 19(1):40-47. PubMed ID: 30918223
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evaluation of Weighted Diffusion Subtraction for Detection of Clinically Significant Prostate Cancer.
    Sato T, Isoda H, Fujimoto K, Furuta A, Fujimoto M, Ito K, Kobayashi T, Nakamoto Y.
    J Magn Reson Imaging; 2021 Dec 10; 54(6):1979-1988. PubMed ID: 34085328
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.